Gram Research analysis shows that a genetic change in the HSD17B13 protein significantly protects against severe liver disease progression. In a 2026 study using mice carrying the human P260S variant, researchers found that this genetic change reduced liver scarring and inflammation by maintaining the liver’s normal cellular organization, even when the liver accumulated more fat. The variant works by reducing the enzyme’s activity and changing its position within liver cells, suggesting a potential new drug target for preventing fatty liver disease from becoming life-threatening.
Scientists have discovered how a specific genetic change in a protein called HSD17B13 protects people from developing serious liver disease. Using specially designed mice that carry this human genetic variant, researchers found that this change reduces liver scarring and inflammation while the liver stores more fat. This discovery could lead to new treatments for fatty liver disease, a condition affecting millions of people worldwide. The findings help explain why some people naturally resist developing severe liver damage, even when they have fatty liver disease.
Key Statistics
A 2026 research study in EBioMedicine found that male mice carrying the human HSD17B13 P260S genetic variant developed significantly reduced liver fibrosis and inflammation compared to normal mice when fed a high-fat diet.
According to research reviewed by Gram, mice with the protective HSD17B13 P260S variant maintained normal liver function and reduced disease progression despite accumulating increased fat in their livers, suggesting that fat storage alone does not cause severe liver damage.
The 2026 study demonstrated that the protective HSD17B13 P260S variant preserves zonated transcriptomic and lipidomic profiles, meaning it maintains the liver’s normal organizational structure at the molecular level, which appears central to disease resistance.
The Quick Take
- What they studied: How a genetic change in the HSD17B13 protein protects against progression from fatty liver disease to severe liver damage with inflammation and scarring.
- Who participated: Male laboratory mice genetically engineered to carry the human P260S variant of the HSD17B13 gene, compared to normal mice, all fed a high-fat diet.
- Key finding: Mice with the protective genetic variant developed significantly less liver scarring and inflammation compared to normal mice, even though they accumulated more fat in their livers.
- What it means for you: This research identifies a potential drug target that could help prevent fatty liver disease from becoming severe. However, this is early-stage research in mice, and human treatments are still years away. People with fatty liver disease should focus on proven approaches like weight loss and dietary changes while researchers develop new therapies.
The Research Details
Researchers created a special strain of male mice that carry the exact human genetic change found in patients who naturally resist severe liver disease. These mice were then fed a high-fat diet to trigger liver disease, similar to how poor diet contributes to fatty liver disease in humans. The scientists examined the mice’s livers using multiple advanced techniques including genetic mapping, imaging, and cellular analysis to understand exactly how the genetic change protects the liver. They compared these mice directly to normal mice eating the same high-fat diet to isolate the effects of the genetic variant.
This approach is valuable because it bridges the gap between laboratory discoveries and human medicine. By using mice that carry the actual human genetic variant rather than a simplified model, the results are more likely to apply to real patients. The combination of multiple analysis techniques provides a complete picture of how the genetic change works at the molecular level, not just whether it works.
This is original research published in a peer-reviewed scientific journal, which means other experts reviewed it before publication. The study uses well-established laboratory techniques and compares the experimental mice to appropriate control mice. However, the research is conducted in animals, not humans, so results may not translate perfectly to people. The specific sample size of mice is not disclosed in the abstract, which limits assessment of statistical power.
What the Results Show
Male mice carrying the P260S genetic variant developed significantly less liver scarring and inflammation when fed a high-fat diet compared to normal mice. This is the key protective effect that makes this genetic change valuable for understanding disease resistance. Interestingly, these protected mice actually accumulated more fat in their livers than normal mice, suggesting that the genetic change allows the liver to tolerate fat accumulation without developing dangerous inflammation and scarring. The protective mice maintained normal liver function despite the increased fat storage, indicating that fat alone does not cause the severe liver damage that occurs in some people.
Advanced genetic analysis revealed that the protective variant maintains a specific pattern of gene activity in different zones of the liver, suggesting the genetic change works by preserving the liver’s normal organizational structure. The variant also reduces the activity of the HSD17B13 enzyme, meaning the protein does less of its normal job, which paradoxically protects the liver. The genetic change appears to work by altering how the protein is positioned within liver cells, affecting which molecules it interacts with.
Previous research in humans showed that people with loss-of-function variants in HSD17B13 are protected from developing severe liver disease, but the exact mechanism was unclear. This mouse study confirms that the human genetic variant works through similar protective mechanisms in a living organism. The findings align with the hypothesis that reducing HSD17B13 activity is beneficial, but add new details about how this protection works at the cellular level.
This research uses only male mice, so results may not apply equally to females, who can have different liver disease patterns. The study uses laboratory mice with engineered genetics rather than naturally occurring variants, which may not perfectly replicate human disease. The findings are from animal models, and what works in mice does not always work in humans. The study does not test any potential treatments, only explains how the genetic protection works.
The Bottom Line
This research is foundational science that identifies a promising drug target but does not yet provide treatment recommendations for patients. People with fatty liver disease should continue following proven approaches: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, exercise regularly, and limit alcohol. Discuss your liver health with your doctor, especially if you have risk factors like obesity or diabetes. This research may eventually lead to new medications, but those are not yet available.
This research is most relevant to people with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease, and their doctors. It is also important for pharmaceutical companies developing new liver disease treatments. People without liver disease can understand this as an example of how genetic research leads to new medicines. This research does not currently apply to treatment decisions for any patient group.
This is early-stage research published in 2026. If a drug targeting HSD17B13 is developed based on these findings, it would typically take 5 to 10 years of additional research and clinical trials before becoming available to patients. Realistic expectations are that this discovery contributes to a pipeline of future treatments rather than providing immediate solutions.
Frequently Asked Questions
What is HSD17B13 and why does it matter for liver disease?
HSD17B13 is a protein that works in liver cells, and having less of it or a non-functional version protects against severe fatty liver disease. A 2026 study found that the P260S genetic variant reduces this protein’s activity, preventing progression to dangerous liver inflammation and scarring.
Can I get tested to see if I have the protective HSD17B13 variant?
Genetic testing for HSD17B13 variants is not yet standard medical practice. This 2026 research is early-stage and focuses on understanding how the variant works. Talk to your doctor about liver disease screening if you have risk factors like obesity or metabolic syndrome.
When will treatments based on this HSD17B13 research be available?
This 2026 study identifies a potential drug target but does not test treatments. Developing a new medication typically takes 5 to 10 years of additional research and clinical trials. Proven approaches like weight loss, diet changes, and exercise remain the current standard for managing fatty liver disease.
Does this research mean I should stop worrying about my diet if I have fatty liver disease?
No. This research explains how one genetic variant provides protection, but most people do not have this variant. Maintaining a healthy weight, eating a balanced diet, exercising regularly, and limiting alcohol remain essential for preventing and managing fatty liver disease.
Why did the mice with the protective variant store more liver fat but stay healthier?
The protective HSD17B13 P260S variant allows the liver to tolerate fat accumulation without developing dangerous inflammation and scarring. The 2026 study found that the variant preserves the liver’s normal cellular organization, suggesting that how fat is stored matters more than the amount stored.
Want to Apply This Research?
- Track liver health markers if you have fatty liver disease: record your weight weekly, monitor energy levels daily, and note any abdominal bloating or discomfort. If you have had liver function blood tests, log the dates and results to track changes over time.
- Use the app to set and track three evidence-based liver health goals: reduce added sugar intake to under 25 grams daily, exercise for 150 minutes weekly, and maintain a calorie deficit if overweight. Log meals and exercise to stay accountable while researchers develop new treatments based on discoveries like this one.
- Establish a quarterly check-in system where you review your progress on liver health behaviors. If you have fatty liver disease, schedule annual liver function tests with your doctor and log the results in the app. Track any changes in symptoms like fatigue or abdominal discomfort to discuss with your healthcare provider.
This article describes early-stage research in laboratory mice and does not provide medical advice or treatment recommendations. The findings have not been tested in humans and may not apply to human patients. If you have fatty liver disease, metabolic syndrome, or concerns about your liver health, consult your healthcare provider for personalized medical advice. Do not make changes to your diet, exercise, or medications based on this research alone. This research identifies a potential future drug target but no treatments based on these findings are currently available.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.